New drug launch prices dip slightly in 2025 but remain historically high, analysis finds
Start here
A joint analysis by ICER and West Health examined the launch prices of newly approved medicines, finding that the median inflation-adjusted net price of drugs launched in 2025 was $257,000, a 35% increase from $173,000 in 2022, despite a slight dip in list prices last year. About one in four new drugs carried annual net prices above $500,000, while 34% fell between $200,000 and $500,000. The median list price rose 24% over the same period to $293,000, and the gap between net and list prices reflects varying discounts across drug types. The findings underscore persistent pressure on payers and patients despite modest movement at the top line.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- STATPickSTAT+: Launch prices for new medicines dipped slightly last year but remain high, analysis finds
A joint analysis by ICER and West Health found the inflation-adjusted median net price of newly launched drugs reached $257,000 in 2025, up 35% from $173,000 in 2022. About one in four new drugs had annual net prices above $500,000, and 34% fell between $200,000 and $500,000; the median list price rose 24% over the same period to $293,000, and the gap between net and list prices reflects varying discounts across drug types.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 20 19:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.